The FDA accepted Merck’s Keytruda + Chemo sBLA application for review in Biliary Tract Cancer

Gilead Science’s Trodelvy showed encouraging results in Breast Cancer

Kite’s Tecartus reported encouraging data in R/R Mantle Cell Lymphoma

Janssen’s Erdafitinib improved Overall Survival versus Chemo in Urothelial Carcinoma

Opdivo + Yervoy showed durable, long-term survival in NSCLC